实用临床医药杂志
實用臨床醫藥雜誌
실용림상의약잡지
JOURNAL OF JIANGSU CLINICAL MEDICINE
2014年
5期
130-132
,共3页
雌二醇%戊酸盐类%雌激素替代疗法%骨密度%骨质疏松
雌二醇%戊痠鹽類%雌激素替代療法%骨密度%骨質疏鬆
자이순%무산염류%자격소체대요법%골밀도%골질소송
estrodiol%valerate%estrogen replacement therapy%bone density%osteoporosis
目的：探讨低剂量性激素治疗方案对绝经后妇女骨量丢失的影响。方法将85例绝经妇女随机分为3组，A 组（30例）：每日服用戊酸雌二醇（E2V）1．0 mg＋醋酸甲羟孕酮（MPA）2．0 mg；B 组（30例）：每日服用结合雌激素（CEE）0．45 mg＋醋酸 MPA 2．0 mg；C 组（对照组，25例）：维生素（VitD）200 IU /d；共服药12个月。各组均每日服用元素钙400 mg。观察3组治疗前后第2-4腰椎骨（L2-4）骨密度、骨代谢生化指标尿 N 端交联多肽/肌酐（NTX /Cr）值，骨折发生率。结果治疗12个月时 B 组 L2～4骨密度上升显著，A 组与 C 组骨密度变化不明显；治疗6个月3组尿 NTX /Cr 值均下降，其中 B 组下降明显。除 B 组与 C 组尿 NTX /Cr 值间差异有统计学意义之外，其余各组间均无统计学意义。结论国产 E2V 1 mg 配伍 MPA 2 mg /d可有效预防绝经后骨丢失。每日 CEE 0．45 mg 与 MPA 2 mg 合用对多数人较合适。
目的：探討低劑量性激素治療方案對絕經後婦女骨量丟失的影響。方法將85例絕經婦女隨機分為3組，A 組（30例）：每日服用戊痠雌二醇（E2V）1．0 mg＋醋痠甲羥孕酮（MPA）2．0 mg；B 組（30例）：每日服用結閤雌激素（CEE）0．45 mg＋醋痠 MPA 2．0 mg；C 組（對照組，25例）：維生素（VitD）200 IU /d；共服藥12箇月。各組均每日服用元素鈣400 mg。觀察3組治療前後第2-4腰椎骨（L2-4）骨密度、骨代謝生化指標尿 N 耑交聯多肽/肌酐（NTX /Cr）值，骨摺髮生率。結果治療12箇月時 B 組 L2～4骨密度上升顯著，A 組與 C 組骨密度變化不明顯；治療6箇月3組尿 NTX /Cr 值均下降，其中 B 組下降明顯。除 B 組與 C 組尿 NTX /Cr 值間差異有統計學意義之外，其餘各組間均無統計學意義。結論國產 E2V 1 mg 配伍 MPA 2 mg /d可有效預防絕經後骨丟失。每日 CEE 0．45 mg 與 MPA 2 mg 閤用對多數人較閤適。
목적：탐토저제량성격소치료방안대절경후부녀골량주실적영향。방법장85례절경부녀수궤분위3조，A 조（30례）：매일복용무산자이순（E2V）1．0 mg＋작산갑간잉동（MPA）2．0 mg；B 조（30례）：매일복용결합자격소（CEE）0．45 mg＋작산 MPA 2．0 mg；C 조（대조조，25례）：유생소（VitD）200 IU /d；공복약12개월。각조균매일복용원소개400 mg。관찰3조치료전후제2-4요추골（L2-4）골밀도、골대사생화지표뇨 N 단교련다태/기항（NTX /Cr）치，골절발생솔。결과치료12개월시 B 조 L2～4골밀도상승현저，A 조여 C 조골밀도변화불명현；치료6개월3조뇨 NTX /Cr 치균하강，기중 B 조하강명현。제 B 조여 C 조뇨 NTX /Cr 치간차이유통계학의의지외，기여각조간균무통계학의의。결론국산 E2V 1 mg 배오 MPA 2 mg /d가유효예방절경후골주실。매일 CEE 0．45 mg 여 MPA 2 mg 합용대다수인교합괄。
Objective To explore the influence of low-dose sex hormone on bone mass loss for postmenopausal women.Methods A total of 85 postmenopausal women were randomly divided into group A,group B and group C.Group A (n =30)was given 1.0 mg estradiol valerate (E2V) and 2.0 mg medroxyprogesterone (MPA)every day.Group B (n =30)was conducted 0.45 mg conjugated estradiol (ethinylestradiol-3-cyclopentylether,CEE)and 2.0 mg MPA every day and group C (control group,n =25)was given vitamin (VitD)200 IU every day.The administration of drugs for each group was 12 months.In addition,400 mg elemental calcium was given daily to all women in the three groups.Bone mineral density (BMD)from the second to the fourth lumbar ver-tebra (L2-4),metabolic bone biochemical markers,urine N-telopeptide /creatinine (NTX /Cr)and incidence of bone fracture were observed before and after drug administration.Results After treat-ment of 12 months,BMD of L2 to L4 increased significantly in group B while it did not increased significantly in groups A and group C.After treatment for 6 months,urine NTX /Cr reduced in the 3 groups,in which the decreased range in group B was the most significant.The difference was sta-tistically significant in NTX /Cr value of group B and group C and there were no significant differ-ence in other groups.Conclusion Domestic E2V for 1 mg combined with 2 mg MPA every day can effectively prevent postmenopausal bone mass loss,and daily administration of CEE for 0.45 mg and MPA for 2 mg is favorable for most postmenopausal women.
